The burden of cancer due to inequalities and its likely causes

Programme stream(s): Cancer control / living with and beyond and cancer outcomes , Early detection / diagnosis and prognosis , Treatment
Programme session type(s): Specialist session

Chair: Yoryos Lyratzopoulos, University College London, UK
Speaker: Jo Waller, University College London, UK
Speaker: Nancy Keating, Harvard Medical School and Dana Farber. USA
Speaker: Bernard Rachet, London School of Hygiene and Tropical Medicine, UK


Room: Hall 1

The session will provide an overview of the state-of-the-evidence on the presence, magnitude and likely cause of inequalities in cancer pathways (with particular emphasis on inequalities in screening, diagnosis and treatment) and survival, and their likely causes.

Social inequalities in cancer screening participation
Speaker: Jo Waller
Affiliation: University College London


Across many developed countries, including the UK, participation in cancer screening is known to vary substantially by socio-economic status (or area-level deprivation) and ethnicity, and such inequalities contribute to poorer cancer outcomes in these demographic groups. The presentation will review existing evidence about inequalities in screening uptake and explore the potential usefulness of the Precaution Adoption Process Model (Weinstein et al, 2008) for understanding non-participatory behaviour, drawing on recent/ongoing research. It will focus on how we can better understand and intervene on psychological processes and behavioural factors that underpin inequalities in screening participation to improve cancer outcomes. The potential role of emotional and psychosocial correlates such as cancer fear, and practical barriers in screening participation will be additionally discussed. Beyond relevant evidence from established or emerging screening programmes (breast, bowel, cervical, lung), the presentation will also discuss the possible contribution of behavioural science in optimising the design and delivery of future screening interventions based on genetic, risk-stratified and novel biomarker technologies.